Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.370
-0.460-2.32%
Volume:4.54M
Turnover:88.69M
Market Cap:16.89B
PE:4.75
High:20.100
Open:19.770
Low:19.240
Close:19.830
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.97
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.076
ROE:1.46%
ROA:-1.24%
PB:1.71
PE(LYR):4.75
PS:3.92

Loading ...

HUTCHMED to Showcase Positive Savolitinib Phase II Results and Broad Fruquintinib/Surufatinib Analyses at 2026 ASCO

Bulletin Express
·
May 22

HUTCHMED says savolitinib Phase II gastric cancer study posts 32.3% response rate

Reuters
·
May 22

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 22

HUTCHMED, Innovent obtain NMPA clearance for ELUNATE-TYVYT regimen in second-line renal cell carcinoma

Bulletin Express
·
May 21

HUTCHMED gains NMPA green light for ELUNATE® + TYVYT® combo in second-line renal cell carcinoma; Innovent secures 10th sintilimab indication

Bulletin Express
·
May 21

HUTCHMED and Innovent Jointly Announce Nmpa Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

THOMSON REUTERS
·
May 21

HUTCHMED Announces Updated Board Composition and Committee Assignments

Bulletin Express
·
May 13

HUTCHMED files directors list with Hong Kong Stock Exchange

Reuters
·
May 13

HUTCHMED gains 99%-plus shareholder support for all AGM motions, green-lights 2026 Share Option Scheme

Bulletin Express
·
May 12

HUTCHMED China Ltd - Announcement on Results of Annual General Meeting

THOMSON REUTERS
·
May 12

HUTCHMED (China) Ltd - Nda for Sovlepenib for Waiha Accepted and Granted Priority Review by China Nmpa

THOMSON REUTERS
·
Apr 29

HUTCHMED (China) Ltd - Announces Nda Acceptance in China With Priority Review and Breakthrough Designation for Sovlepenib

THOMSON REUTERS
·
Apr 29

HUTCHMED Gets NMPA Priority Review for Sovleplenib NDA Targeting Warm Autoimmune Hemolytic Anemia

Bulletin Express
·
Apr 29

HUTCHMED's Sovleplenib NDA for Warm Autoimmune Hemolytic Anemia Accepted in China with Priority Review and Breakthrough Therapy Designation

Stock News
·
Apr 29

HUTCHMED says China NMPA accepts sovleplenib wAIHA NDA for priority review

Reuters
·
Apr 29

HUTCHMED (China) Ltd - Phase Trial for Sovleplenib in Waha Met Primary Endpoint in January 2026

THOMSON REUTERS
·
Apr 29

HUTCHMED (China) Ltd - Nda for Sovleplenib in Waha Accepted With Priority Review by Nmpa

THOMSON REUTERS
·
Apr 29

HUTCHMED Announces Nda Acceptance in China With Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

THOMSON REUTERS
·
Apr 29

HUTCHMED to present new HMPL-A580 preclinical data at AACR annual meeting

Reuters
·
Apr 09

HUTCHMED Introduces 10-Year Share Option Scheme with 5% Issuance Cap and Strict Governance Framework

Bulletin Express
·
Apr 09